{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T03:13:44Z","timestamp":1785035624889,"version":"3.55.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s12325-023-02555-5","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T14:02:12Z","timestamp":1686578532000},"page":"3381-3394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Management of Advanced Invasive Melanoma: New Strategies"],"prefix":"10.1007","volume":"40","author":[{"given":"Alessia","family":"Villani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Scalvenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Micali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Lacarrubba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Martora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"issue":"4","key":"2555_CR1","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3892\/ijo.2018.4287","volume":"52","author":"GC Leonardi","year":"2018","unstructured":"Leonardi GC, Falzone L, Salemi R, et al. Cutaneous melanoma: from pathogenesis to therapy (review). Int J Oncol. 2018;52(4):1071\u201380. https:\/\/doi.org\/10.3892\/ijo.2018.4287.","journal-title":"Int J Oncol"},{"issue":"3","key":"2555_CR2","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s13555-021-00525-9","volume":"11","author":"A Villani","year":"2021","unstructured":"Villani A, Scalvenzi M, Fabbrocini G, Ocampo-Candiani J, Ocampo-Garza SS. Looking into a better future: novel therapies for metastatic melanoma. Dermatol Ther (Heidelb). 2021;11(3):751\u201367. https:\/\/doi.org\/10.1007\/s13555-021-00525-9.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"2555_CR3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/DAD.0b013e31828a2ec5","volume":"36","author":"O Abbas","year":"2014","unstructured":"Abbas O, Miller DD, Bhawan J. Cutaneous malignant melanoma: update on diagnostic and prognostic biomarkers. Am J Dermatopathol. 2014;36(5):363\u201379. https:\/\/doi.org\/10.1097\/DAD.0b013e31828a2ec5.","journal-title":"Am J Dermatopathol"},{"key":"2555_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105384","author":"J T\u00edm\u00e1r","year":"2022","unstructured":"T\u00edm\u00e1r J, Lad\u00e1nyi A. Molecular pathology of skin melanoma: epidemiology, differential diagnostics, prognosis and therapy prediction. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23105384.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2555_CR5","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1111\/jdv.18545","volume":"37","author":"A Villani","year":"2023","unstructured":"Villani A, Scalvenzi M, Fabbrocini G, Fornaro L, Guerrasio G, Potestio L. Effects of COVID-19 pandemic on malignant melanoma diagnosis. J Eur Acad Dermatol Venereol. 2023;37(1):e22\u20133. https:\/\/doi.org\/10.1111\/jdv.18545.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"2555_CR6","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1080\/09546634.2020.1818674","volume":"33","author":"A Villani","year":"2022","unstructured":"Villani A, Fabbrocini G, Scalvenzi M. The reduction in the detection of melanoma during the coronavirus disease 2019 (COVID-19) pandemic in a melanoma center of South Italy. J Dermatol Treat. 2022;33(3):1778. https:\/\/doi.org\/10.1080\/09546634.2020.1818674.","journal-title":"J Dermatol Treat"},{"issue":"6","key":"2555_CR7","first-page":"1005","volume":"28","author":"M Rastrelli","year":"2014","unstructured":"Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014;28(6):1005\u201311.","journal-title":"In Vivo"},{"issue":"4","key":"2555_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cps.2021.05.001","volume":"48","author":"WW Dzwierzynski","year":"2021","unstructured":"Dzwierzynski WW. Melanoma risk factors and prevention. Clin Plast Surg. 2021;48(4):543\u201350. https:\/\/doi.org\/10.1016\/j.cps.2021.05.001.","journal-title":"Clin Plast Surg"},{"issue":"4","key":"2555_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1615\/CritRevEukaryotGeneExpr.2020028454","volume":"30","author":"B Ahmed","year":"2020","unstructured":"Ahmed B, Qadir MI, Ghafoor S. Malignant melanoma: skin cancer-diagnosis, prevention, and treatment. Crit Rev Eukaryot Gene Expr. 2020;30(4):291\u20137. https:\/\/doi.org\/10.1615\/CritRevEukaryotGeneExpr.2020028454.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"2","key":"2555_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/CMR.0000000000000312","volume":"27","author":"R Minini","year":"2017","unstructured":"Minini R, Rohrmann S, Braun R, Korol D, Dehler S. Incidence trends and clinical-pathological characteristics of invasive cutaneous melanoma from 1980 to 2010 in the Canton of Zurich, Switzerland. Melanoma Res. 2017;27(2):145\u201351. https:\/\/doi.org\/10.1097\/CMR.0000000000000312.","journal-title":"Melanoma Res"},{"issue":"3","key":"2555_CR11","first-page":"705","volume":"29","author":"WHJ Clark","year":"1969","unstructured":"Clark WHJ, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29(3):705\u201327.","journal-title":"Cancer Res"},{"issue":"10","key":"2555_CR12","doi-asserted-by":"publisher","first-page":"e623","DOI":"10.1111\/jdv.16500","volume":"34","author":"A Villani","year":"2020","unstructured":"Villani A, Fabbrocini G, Costa C, Greco V, Scalvenzi M. Second primary melanoma: incidence rate and risk factors. J Eur Acad Dermatol Venereol. 2020;34(10):e623\u20134. https:\/\/doi.org\/10.1111\/jdv.16500.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2555_CR13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.ejca.2022.03.008","volume":"170","author":"C Garbe","year":"2022","unstructured":"Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: diagnostics: update 2022. Eur J Cancer. 2022;170:236\u201355. https:\/\/doi.org\/10.1016\/j.ejca.2022.03.008.","journal-title":"Eur J Cancer"},{"issue":"6","key":"2555_CR14","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/PAS.0000000000001034","volume":"42","author":"G Saldanha","year":"2018","unstructured":"Saldanha G, Yarrow J, Pancholi J, et al. Breslow density is a novel prognostic feature that adds value to melanoma staging. Am J Surg Pathol. 2018;42(6):715\u201325. https:\/\/doi.org\/10.1097\/PAS.0000000000001034.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2555_CR15","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","volume":"80","author":"SM Swetter","year":"2019","unstructured":"Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208\u201350. https:\/\/doi.org\/10.1016\/j.jaad.2018.08.055.","journal-title":"J Am Acad Dermatol"},{"key":"2555_CR16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","volume":"170","author":"C Garbe","year":"2022","unstructured":"Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment\u2014update 2022. Eur J Cancer. 2022;170:256\u201384. https:\/\/doi.org\/10.1016\/j.ejca.2022.04.018.","journal-title":"Eur J Cancer"},{"key":"2555_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126388","author":"A Villani","year":"2022","unstructured":"Villani A, Potestio L, Fabbrocini G, Troncone G, Malapelle U, Scalvenzi M. The treatment of advanced melanoma: therapeutic update. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23126388.","journal-title":"Int J Mol Sci"},{"issue":"10151","key":"2555_CR18","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet (London, England). 2018;392(10151):971\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(18)31559-9.","journal-title":"Lancet (London, England)"},{"issue":"4","key":"2555_CR19","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1111\/jdv.17831","volume":"36","author":"A Villani","year":"2022","unstructured":"Villani A, Scalvenzi M, Peduto T, Cinelli E, Fabbrocini G, Di Stefani A. Dermoscopy and reflectance confocal microscopy of Kaposi\u2019s sarcoma: an overview. J Eur Acad Dermatol Venereol. 2022;36(4):e272\u20134. https:\/\/doi.org\/10.1111\/jdv.17831.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"2555_CR20","doi-asserted-by":"publisher","first-page":"e394","DOI":"10.1111\/ijd.16036","volume":"61","author":"L Potestio","year":"2022","unstructured":"Potestio L, Villani A, Ocampo-Garza SS, et al. Dermatophytid evaluated by in vivo reflectance confocal microscopy: a new approach? Int J Dermatol. 2022;61(10):e394\u20136. https:\/\/doi.org\/10.1111\/ijd.16036.","journal-title":"Int J Dermatol"},{"issue":"5","key":"2555_CR21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/14737140.2019.1593829","volume":"19","author":"M Agozzino","year":"2019","unstructured":"Agozzino M, Moscarella E, Babino G, Caccavale S, Piccolo V, Argenziano G. The use of in vivo reflectance confocal microscopy for the diagnosis of melanoma. Expert Rev Anticancer Ther. 2019;19(5):413\u201321. https:\/\/doi.org\/10.1080\/14737140.2019.1593829.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"2555_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.det.2022.07.006","volume":"41","author":"N Golda","year":"2023","unstructured":"Golda N, Hruza G. Mohs micrographic surgery. Dermatol Clin. 2023;41(1):39\u201347. https:\/\/doi.org\/10.1016\/j.det.2022.07.006.","journal-title":"Dermatol Clin"},{"issue":"9","key":"2555_CR23","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00018-003-2324-4","volume":"60","author":"M Poetsch","year":"2003","unstructured":"Poetsch M, Dittberner T, Woenckhaus C. Can different genetic changes characterize histogenetic subtypes and biologic behavior in sporadic malignant melanoma of the skin? Cell Mol Life Sci. 2003;60(9):1923\u201332. https:\/\/doi.org\/10.1007\/s00018-003-2324-4.","journal-title":"Cell Mol Life Sci"},{"issue":"23","key":"2555_CR24","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMra2034861","volume":"384","author":"BD Curti","year":"2021","unstructured":"Curti BD, Faries MB. Recent advances in the treatment of melanoma. N Engl J Med. 2021;384(23):2229\u201340. https:\/\/doi.org\/10.1056\/NEJMra2034861.","journal-title":"N Engl J Med"},{"issue":"3","key":"2555_CR25","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/jso.26229","volume":"123","author":"AY Lee","year":"2021","unstructured":"Lee AY, Brady MS. Neoadjuvant immunotherapy for melanoma. J Surg Oncol. 2021;123(3):782\u20138. https:\/\/doi.org\/10.1002\/jso.26229.","journal-title":"J Surg Oncol"},{"key":"2555_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ejca.2021.08.044","volume":"158","author":"MM de Meza","year":"2021","unstructured":"de Meza MM, Ismail RK, Rauwerdink D, et al. Adjuvant treatment for melanoma in clinical practice\u2014trial versus reality. Eur J Cancer. 2021;158:234\u201345. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.044.","journal-title":"Eur J Cancer"},{"key":"2555_CR27","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0690","author":"JM DeRogatis","year":"2022","unstructured":"DeRogatis JM, Viramontes KM, Neubert EN, Henriquez ML, Guerrero-Juarez CF, Tinoco R. Targeting the PSGL-1 immune checkpoint promotes immunity to PD-1 resistant melanoma. Cancer Immunol Res. 2022. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-0690.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2555_CR28","doi-asserted-by":"publisher","DOI":"10.4110\/in.2022.22.e2","volume":"22","author":"JB Lee","year":"2022","unstructured":"Lee JB, Kim HR, Ha SJ. Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy. Immune Netw. 2022;22(1): e2. https:\/\/doi.org\/10.4110\/in.2022.22.e2.","journal-title":"Immune Netw."},{"issue":"6","key":"2555_CR29","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.4103\/jcrt.JCRT_1290_16","volume":"14","author":"V Koppolu","year":"2018","unstructured":"Koppolu V, RekhaVasigala VK. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. J Cancer Res Ther. 2018;14(6):1167\u201375. https:\/\/doi.org\/10.4103\/jcrt.JCRT_1290_16.","journal-title":"J Cancer Res Ther"},{"key":"2555_CR30","unstructured":"European Medicines Agency. ODIVO (Nivolumab): summary of product characteristics. 2014. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf. Accessed on Mar 16, 2023."},{"issue":"4","key":"2555_CR31","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","volume":"36","author":"J Larkin","year":"2018","unstructured":"Larkin J, Minor D, D\u2019Angelo S, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(4):383\u201390. https:\/\/doi.org\/10.1200\/JCO.2016.71.8023.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"2555_CR32","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1412082.","journal-title":"N Engl J Med"},{"issue":"11","key":"2555_CR33","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(18)30700-9.","journal-title":"Lancet Oncol"},{"issue":"11","key":"2555_CR34","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","volume":"21","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Del Vecchio M, Mandal\u00e1 M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(11):1465\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(20)30494-0.","journal-title":"Lancet Oncol"},{"key":"2555_CR35","unstructured":"European Medicines Agency. KEYTRUDA (Pemrbolizumab): summary of product characteristics. 2015. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf. Accessed on Mar 16, 2023."},{"issue":"8","key":"2555_CR36","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(15)00083-2.","journal-title":"Lancet Oncol"},{"issue":"10105","key":"2555_CR37","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet (London, England). 2017;390(10105):1853\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(17)31601-X.","journal-title":"Lancet (London, England)"},{"issue":"5","key":"2555_CR38","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","volume":"22","author":"AMM Eggermont","year":"2021","unstructured":"Eggermont AMM, Blank CU, Mandal\u00e0 M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(5):643\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(21)00065-6.","journal-title":"Lancet Oncol"},{"key":"2555_CR39","unstructured":"European Medicines Agency. YERVOY (Ipilimumab): summary of product characteristics. 2011. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/yervoy-epar-product-information_en.pdf. Accessed on Mar 16, 2023."},{"key":"2555_CR40","unstructured":"European Medicines Agency. TAFINLAR (Dabrafenib): Summary of Product Characteristics. 2013. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tafinlar-epar-product-information_en.pdf. Accessed on Mar 16, 2023."},{"issue":"7","key":"2555_CR41","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1634\/theoncologist.2014-0429","volume":"20","author":"NR Latimer","year":"2015","unstructured":"Latimer NR, Abrams KR, Amonkar MM, Stapelkamp C, Swann RS. Adjusting for the confounding effects of treatment switching\u2014the BREAK-3 trial: dabrafenib versus dacarbazine. Oncologist. 2015;20(7):798\u2013805. https:\/\/doi.org\/10.1634\/theoncologist.2014-0429.","journal-title":"Oncologist"},{"issue":"7","key":"2555_CR42","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1904059.","journal-title":"N Engl J Med"},{"issue":"3","key":"2555_CR43","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S1470-2045(20)30062-0","volume":"21","author":"R Dummer","year":"2020","unstructured":"Dummer R, Brase JC, Garrett J, et al. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF(V600)-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020;21(3):358\u201372. https:\/\/doi.org\/10.1016\/S1470-2045(20)30062-0.","journal-title":"Lancet Oncol"},{"key":"2555_CR44","unstructured":"European Medicines Agency. MEKINIST (Trametinib): summary of product characteristics. 2014. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mekinist-epar-product-information_en.pdf. Accessed on Mar 16, 2023."},{"issue":"5","key":"2555_CR45","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/cam4.643","volume":"5","author":"NR Latimer","year":"2016","unstructured":"Latimer NR, Bell H, Abrams KR, Amonkar MM, Casey M. Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy. Cancer Med. 2016;5(5):806\u201315. https:\/\/doi.org\/10.1002\/cam4.643.","journal-title":"Cancer Med"},{"key":"2555_CR46","unstructured":"European Medicines Agency. ZELBORAF (Vemurafenib): summary of product characteristics. 2012. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zelboraf-epar-product-information_en.pdf. Accessed on Mar 16, 2023."},{"key":"2555_CR47","unstructured":"European Medicines Agency. BRAFTOVI (Encorafenib): summary of product characteristics. 2018. Encorafenib. 2018. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/braftovi-epar-product-information_en.pdf. Accessed on Mar 16, 2022."},{"key":"2555_CR48","unstructured":"European Medicines Agency. MEKTOVI (Binimetinib): summary of product characteristics. 2018. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mektovi-epar-product-information_en.pdf. Accessed on Mar 16, 2023."},{"key":"2555_CR49","unstructured":"European Medicines Agency. IMLYGIC (Talimogene laherparepvec): summary of product characteristics. 2020. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imlygic-epar-product-information_en.pdf. Accessed on Mar 16, 2023."},{"issue":"20","key":"2555_CR50","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","volume":"34","author":"SL Goff","year":"2016","unstructured":"Goff SL, Dudley ME, Citrin DE, et al. Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(20):2389\u201397. https:\/\/doi.org\/10.1200\/JCO.2016.66.7220.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"2555_CR51","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00262-019-02383-z","volume":"68","author":"B Weide","year":"2019","unstructured":"Weide B, Eigentler T, Catania C, et al. A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. Cancer Immunol Immunother. 2019;68(9):1547\u201359. https:\/\/doi.org\/10.1007\/s00262-019-02383-z.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"2555_CR52","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1111\/jocd.14938","volume":"21","author":"M Megna","year":"2022","unstructured":"Megna M, Camela E, Villani A, Tajani A, Fabbrocini G, Potestio L. Teledermatology: a useful tool also after COVID-19 era? J Cosmet Dermatol. 2022;21(6):2309\u201310. https:\/\/doi.org\/10.1111\/jocd.14938.","journal-title":"J Cosmet Dermatol"},{"issue":"28","key":"2555_CR53","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.2217\/fon-2020-0351","volume":"16","author":"NI Khushalani","year":"2020","unstructured":"Khushalani NI, Diab A, Ascierto PA, et al. Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. Future Oncol. 2020;16(28):2165\u201375. https:\/\/doi.org\/10.2217\/fon-2020-0351.","journal-title":"Future Oncol"},{"issue":"6","key":"2555_CR54","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(14)70110-X","volume":"15","author":"PG Corrie","year":"2014","unstructured":"Corrie PG, Marshall A, Dunn JA, et al. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncol. 2014;15(6):620\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(14)70110-X.","journal-title":"Lancet Oncol"},{"key":"2555_CR55","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan3311","author":"NJ Neubert","year":"2018","unstructured":"Neubert NJ, Schmittnaegel M, Bordry N, et al. T cell-induced CSF1 promotes melanoma resistance to PD1 blockade. Sci Transl Med. 2018. https:\/\/doi.org\/10.1126\/scitranslmed.aan3311.","journal-title":"Sci Transl Med."},{"issue":"11","key":"2555_CR56","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1158\/1078-0432.CCR-18-2740","volume":"25","author":"KH Jung","year":"2019","unstructured":"Jung KH, LoRusso P, Burris H, et al. Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (Atezolizumab) in advanced solid tumors. Clin Cancer Res. 2019;25(11):3220\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2740.","journal-title":"Clin Cancer Res"},{"key":"2555_CR57","doi-asserted-by":"publisher","first-page":"7347","DOI":"10.2147\/OTT.S214211","volume":"12","author":"J Deng","year":"2019","unstructured":"Deng J, Zhao S, Zhang X, et al. OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer. Onco Targets Ther. 2019;12:7347\u201353. https:\/\/doi.org\/10.2147\/OTT.S214211.","journal-title":"Onco Targets Ther"},{"issue":"5","key":"2555_CR58","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41591-019-0420-8","volume":"25","author":"R Zappasodi","year":"2019","unstructured":"Zappasodi R, Sirard C, Li Y, et al. Rational design of anti-GITR-based combination immunotherapy. Nat Med. 2019;25(5):759\u201366. https:\/\/doi.org\/10.1038\/s41591-019-0420-8.","journal-title":"Nat Med"},{"issue":"4","key":"2555_CR59","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1111\/jdv.15469","volume":"33","author":"M Scalvenzi","year":"2019","unstructured":"Scalvenzi M, Costa C, Cappello M, Villani A. Reply to Woltsche N. et al. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single-centre experience. J Eur Acad Dermatol Venereol. 2019;33(4):e145\u20137. https:\/\/doi.org\/10.1111\/jdv.15469.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"2555_CR60","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1111\/jocd.13519","volume":"19","author":"A Villani","year":"2020","unstructured":"Villani A, Annunziata MC, Abategiovanni L, Fabbrocini G. Teledermatology for acne patients: how to reduce face-to-face visits during COVID-19 pandemic. J Cosmet Dermatol. 2020;19(8):1828. https:\/\/doi.org\/10.1111\/jocd.13519.","journal-title":"J Cosmet Dermatol"},{"issue":"3","key":"2555_CR61","doi-asserted-by":"publisher","first-page":"1903827","DOI":"10.1080\/21645515.2021.1903827","volume":"18","author":"L Tagliaferri","year":"2022","unstructured":"Tagliaferri L, Lancellotta V, Fionda B, et al. Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review. Hum Vaccin Immunother. 2022;18(3):1903827. https:\/\/doi.org\/10.1080\/21645515.2021.1903827.","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"2555_CR62","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1080\/14740338.2020.1837773","volume":"19","author":"A Villani","year":"2020","unstructured":"Villani A, Cinelli E, Fabbrocini G, Lallas A, Scalvenzi M. Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits. Expert Opin Drug Saf. 2020;19(12):1585\u201394. https:\/\/doi.org\/10.1080\/14740338.2020.1837773.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"2555_CR63","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac063","volume":"27","author":"A Villani","year":"2022","unstructured":"Villani A, Fabbrocini G, Costa C, Potestio L, Scalvenzi M. Sonidegib with and without adjunctive treatment for locally advanced basal cell carcinomas. Oncologist. 2022;27(6): e533. https:\/\/doi.org\/10.1093\/oncolo\/oyac063.","journal-title":"Oncologist"},{"key":"2555_CR64","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15786","author":"A Villani","year":"2022","unstructured":"Villani A, Potestio L, Fabbrocini G, di Vico F, Costa C, Scalvenzi M. Long-term efficacy of telemedicine for patients with locally advanced basal cell carcinoma during COVID-19 pandemic. Dermatol Ther. 2022. https:\/\/doi.org\/10.1111\/dth.15786.","journal-title":"Dermatol Ther"},{"issue":"3","key":"2555_CR65","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1007\/s12325-022-02044-1","volume":"39","author":"A Villani","year":"2022","unstructured":"Villani A, Potestio L, Fabbrocini G, Scalvenzi M. New emerging treatment options for advanced basal cell carcinoma and squamous cell carcinoma. Adv Ther. 2022;39(3):1164\u201378. https:\/\/doi.org\/10.1007\/s12325-022-02044-1.","journal-title":"Adv Ther"},{"issue":"1","key":"2555_CR66","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/14740338.2022.1993819","volume":"21","author":"A Villani","year":"2022","unstructured":"Villani A, Ocampo-Garza SS, Potestio L, et al. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. Expert Opin Drug Saf. 2022;21(1):21\u20139. https:\/\/doi.org\/10.1080\/14740338.2022.1993819.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"2555_CR67","doi-asserted-by":"publisher","first-page":"758","DOI":"10.4103\/ijdvl.IJDVL_92_18","volume":"84","author":"M Scalvenzi","year":"2018","unstructured":"Scalvenzi M, Villani A, Mazzella C, Cappello M, Salvatores GDF, Costa C. Vismodegib treatment in a HIV positive patient on antiretroviral therapy. Indian J Dermatol Venereol Leprol. 2018;84(6):758\u201360. https:\/\/doi.org\/10.4103\/ijdvl.IJDVL_92_18.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"2555_CR68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jid.2020.03.943","volume":"141","author":"RW Jenkins","year":"2021","unstructured":"Jenkins RW, Fisher DE. Treatment of advanced melanoma in 2020 and beyond. J Invest Dermatol. 2021;141(1):23\u201331. https:\/\/doi.org\/10.1016\/j.jid.2020.03.943.","journal-title":"J Invest Dermatol"},{"key":"2555_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21238984","author":"K Eddy","year":"2020","unstructured":"Eddy K, Chen S. Overcoming immune evasion in melanoma. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21238984.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2555_CR70","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/pcmr.12880","volume":"34","author":"GM Alicea","year":"2021","unstructured":"Alicea GM, Rebecca VW. Emerging strategies to treat rare and intractable subtypes of melanoma. Pigment Cell Melanoma Res. 2021;34(1):44\u201358. https:\/\/doi.org\/10.1111\/pcmr.12880.","journal-title":"Pigment Cell Melanoma Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02555-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02555-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02555-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T13:21:38Z","timestamp":1692796898000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02555-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":70,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2555"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02555-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]},"assertion":[{"value":"12 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}